Newsletter October 2018

Children's Brain Tumour Drug Delivery Consortium

Accelerating Progress in Drug Delivery

Internationally collaborative grant applications

We maintain a list of funding opportunities on our website. If you know of a funding call that should be included, please send us the details.



We have received several requests from non-UK based researchers who are keen to work with UK researchers to jointly submit applications to UK funders.

We'd like all researchers working in fields relevant to drug delivery to the brain to be able to find the collaborators they need to submit strong applications. Please help make this a reality by submitting your research details for inclusion in the research database (if you haven't already done so), and by spreading the word about this tool amongst your academic colleagues.

Conference notice

The Blood Brain Barrier Conference, 3-6 April 2019, New York, is open for abstract submission (deadline Jan 18th), stating that '*the majority of oral presentations will be drawn from openly submitted abstracts*'.

It would be great if the drug delivery community secured some speaker slots, so please do consider submitting.

Two other highly relevant meetings are the 3rd CNS Anticancer Drug Discovery and Development Conference (14-15 November, New Orleans) and the Blood-Brain Barrier and CNS Drug Discovery Conference (12 April, San Diego).

We'd love to know if you're planning to attend any of these conferences. Please also help spread the word amongst your contacts. Thank you.

Children's Brain Tumour Drug Delivery Consortium
Accelerating Progress in Drug Delivery

Upcoming Conferences

5-6 October – cns tumors: Innovative Technology that Advances Patient Care
Houston, Texas, USA

10 October – First EANO-SNO Brain Tumor Club
Stockholm, Sweden

10-14 October - EANO 2018
Stockholm, Sweden

19-23 October – ESMO 2018 Munich, Germany

24-25 October – 13th International Conference on Biopharma and Biotherapeutics
Boston, USA

26 October – 8th Annual Brain Tumor Symposium
Philadelphia, USA

3-7 November – Neuroscience 2018
San Diego, USA

4-6 November – 2018 NCRI Cancer Conference
Glasgow, UK

14-15 November – 3rd CNS Anticancer Drug Discovery and Development Conference
New Orleans, USA

15-18 November – 2018 SNO Meeting
New Orleans, USA

16-19 November – Society of Paediatric Oncology (SIOP)
Kyoto, Japan

More conference are listed on our website, here.

Spotlight

In this newsletter, we feature Renishaw plc employee Dr Max Woolley.

Max has worked in engineering design for over 35 years, half in academia - researching design and development strategies for optimising medical device design. In his current role as Technical Fellow, Max manages a team in researching and designing innovative intraparenchymal drug delivery systems for neuro-degenerative and neuro-oncology indications. He is named inventor on numerous medical device patents and co-author of peer reviewed journal articles across the fields of engineering design, bio-mechanics and implantable medical device performance.

Intraparenchymal drug delivery offers a practical method of bypassing the blood-brain barrier and shows great promise in providing the next step change in the treatment of neuro-degenerative, neuro-oncology and other debilitating neurological conditions.

Renishaw is developing a patented range of engineering solutions to cover chronic (long-term implantable) and acute (short-term implantable) intraparenchymal drug delivery. Our low dead volume chronic device has a novel, MRI compatible, transcutaneous port that aims to provide a solution for simultaneous intermittent drug delivery through multiple catheters (up to four) at any time interval.

Over several years Renishaw has been working with experienced clinical experts to produce a specification for an intraparenchymal drug delivery device and stereotactic delivery platform that facilitates convection enhanced delivery (CED) and other infusion applications.

The chronic product is currently undergoing clinical investigation as part of the Horizon 2020 funded TreatER project. TreatER is a first-in-human clinical study examining the intraparenchymal delivery of CDNF for the treatment of Parkinson's disease. For more information visit www.renishaw.com/drugdelivery or watch a video.

Children's Brain Tumour Drug Delivery Consortium
Accelerating Progress in Drug Delivery

Contact details

Email:
cbtddc@nottingham.ac.uk

Website:
www.cbtddc.org

Twitter:
Follow us @cbtddc

Collaborative research database:
http://www.cbtddc.org/research/list.aspx

Image/video of the month

Video showing how intranasal drug delivery can be coupled with focused ultrasound and microbubbles to circumvent the blood-brain barrier and target drugs to specific regions of the brain. *Click on link embedded in image.*

Video kindly supplied by Dr Hong Chen, assistant professor of biomedical engineering in the School of Engineering & Applied Science, and assistant professor of radiation oncology at Washington University School of Medicine in St. Louis.

To share an image or video in this newsletter, please send us the file plus a caption.